We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Zoetis (ZTS - Free Report) closed at $182.76, marking a +1.53% move from the previous day. This change outpaced the S&P 500's 0.27% gain on the day. Meanwhile, the Dow gained 0.65%, and the Nasdaq, a tech-heavy index, added 0.26%.
Shares of the animal health company have depreciated by 7.6% over the course of the past month, underperforming the Medical sector's loss of 4.14% and the S&P 500's gain of 2%.
The upcoming earnings release of Zoetis will be of great interest to investors. The company's earnings report is expected on November 4, 2024. The company's upcoming EPS is projected at $1.46, signifying a 7.35% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $2.29 billion, indicating a 6.3% increase compared to the same quarter of the previous year.
ZTS's full-year Zacks Consensus Estimates are calling for earnings of $5.83 per share and revenue of $9.19 billion. These results would represent year-over-year changes of +9.59% and +7.51%, respectively.
Investors should also pay attention to any latest changes in analyst estimates for Zoetis. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been a 0.1% fall in the Zacks Consensus EPS estimate. Right now, Zoetis possesses a Zacks Rank of #3 (Hold).
Looking at valuation, Zoetis is presently trading at a Forward P/E ratio of 30.88. This indicates a premium in contrast to its industry's Forward P/E of 16.76.
Investors should also note that ZTS has a PEG ratio of 2.79 right now. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Drugs industry currently had an average PEG ratio of 1.4 as of yesterday's close.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 81, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Zoetis (ZTS - Free Report) closed at $182.76, marking a +1.53% move from the previous day. This change outpaced the S&P 500's 0.27% gain on the day. Meanwhile, the Dow gained 0.65%, and the Nasdaq, a tech-heavy index, added 0.26%.
Shares of the animal health company have depreciated by 7.6% over the course of the past month, underperforming the Medical sector's loss of 4.14% and the S&P 500's gain of 2%.
The upcoming earnings release of Zoetis will be of great interest to investors. The company's earnings report is expected on November 4, 2024. The company's upcoming EPS is projected at $1.46, signifying a 7.35% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $2.29 billion, indicating a 6.3% increase compared to the same quarter of the previous year.
ZTS's full-year Zacks Consensus Estimates are calling for earnings of $5.83 per share and revenue of $9.19 billion. These results would represent year-over-year changes of +9.59% and +7.51%, respectively.
Investors should also pay attention to any latest changes in analyst estimates for Zoetis. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been a 0.1% fall in the Zacks Consensus EPS estimate. Right now, Zoetis possesses a Zacks Rank of #3 (Hold).
Looking at valuation, Zoetis is presently trading at a Forward P/E ratio of 30.88. This indicates a premium in contrast to its industry's Forward P/E of 16.76.
Investors should also note that ZTS has a PEG ratio of 2.79 right now. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Drugs industry currently had an average PEG ratio of 1.4 as of yesterday's close.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 81, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.